within the swiftly evolving area of oncology investigate, precise and efficient mutation screening is crucial for building focused therapies. The KRAS providers System plays a pivotal part Within this landscape by presenting extensive solutions for KRAS mutation profiling and Evaluation. KRAS mutations, found in roughly 95% of RAS-related oncogenic